Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04612530
Other study ID # 2020.231 - NL73415.029.20
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 1, 2020
Est. completion date June 1, 2023

Study information

Verified date December 2022
Source Amsterdam UMC, location VUmc
Contact Florentine EF Timmer, MSc
Phone +3120 444 4571
Email f.timmer1@amsterdamumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Irreversible electroporation is a local ablative technique used in the treatment of pancreatic cancer. In addition to its cytoreductive ability, IRE also induces a systemic immune response. However, this immune response is not potent enough to establish durable regression of the tumor. The immune response can be leveraged by combining IRE with immunotherapy. The primary aim of this study is to determine the safety of IRE + Nivolumab (arm B) and IRE + Nivolumab + CpG (arm C). The secondary aim is to assess efficacy of the experimental arms (B, C) and control arm A (Nivolumab monotherapy), based on overall and progression-free survival as well as locoregional and systemic immune modulation.


Description:

Pancreatic carcinoma is one of the deadliest types of cancer. In contrast to other cancers, new treatment options have demonstrated only moderate improvements for pancreatic cancer in terms of overall survival. Patients with metastasized disease (stage IV, AJCC) that are treated with chemotherapy in the Netherlands currently present a median overall survival of 6.4 months. Previous research has shown promising results for patients with locally advanced pancreatic cancer (LAPC, stage III, AJCC) with regards to combination treatment with chemotherapy and irreversible electroporation (IRE), a local ablation technique that utilizes electrical pulses to destroy cancerous tissue. In addition to an increase in overall survival, IRE induced a systemic immune response. However, the immune response was not potent enough to generate a lasting anti-tumor effect. Leveraging the body's own immune response by using local and systemic immunotherapy may create a synergistic effect, potentially inducing a durable anti-tumor response. The PANFIRE-III is a prospective randomised phase 1 trial with the primary aim to determine safety of the combination therapies IRE + Nivolumab (arm B) and CpG + IRE + Nivolumab (arm C) in patients with oligo-metastasized pancreatic cancer. The secondary goal is to determine efficacy of the experimental arms (arm B, C) compared to the control arm A (Nivolumab monotherapy). This will be assessed by looking at the overall and progression-free survival as well as the locoregional and systemic immune response. The treatment combination of IRE with immunotherapy has the potential to generate systemic protection by in vivo vaccination against pancreatic cancer cells, hereby inhibiting both local and distant tumor growth.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date June 1, 2023
Est. primary completion date April 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Radiological and histopathologically proven stage IV pancreatic cancer (according to the AJCC staging system for pancreatic cancer); - Primary oligometastatic disease, defined as at least 1 hepatic metastasis but occurrence of other metastases is not necessarily restricted to the liver, maximum of metastases is to be determined on a case by case basis by the multidisciplinary tumor board. - Primary tumor is in situ. - A minimum of 4 cycles of FOLFIRINOX chemotherapy is required but with the explicit aim to strive for completion of 8 cycles of FOLFIRINOX before study inclusion, with at least stable disease on CTscan. - Age = 18 years. - World Health Organisation scale (WHO) performance status 0 - 2; - Adequate bile drainage in case of biliary obstruction. Exclusion Criteria: - Trans-mucosal tumor invasion into surrounding duodenum or stomach; - Active epilepsy (last convulsion < 5 years); - History of cardiac disease: - Congestive heart failure > NYHA Class 2 - Active coronary artery disease (defined as myocardial infarction within 6 months prior to screening); - Ventricular cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers for antihypertensive regimen are permitted; atrial fibrillation is not contra-indicated); - Known hypersensitivity to any oligodeoxynucleotides. - Compromised liver function defined as warning signs of portal hypertension, INR > 1,5 without use of anticoagulants, bilirubin > x 1.5 Upper limit of normal range (ULN) ASAT >3.0 x ULN, ALAT >3.0 x ULN. - Compromised kidney function defined as eGFR <30 ml/min (using the Cockcroft Gault formula); - Active autoimmune disease requiring disease-modifying therapy at the time of screening: i.e. > 10 mg prednisolone per day or equivalent to this regimen. - Uncontrolled hypertension. Blood pressure must be =160/95 mmHg at the time of screening on a stable antihypertensive regimen; - Uncontrolled infections (> grade 2 NCI-CTC version 3.0); requiring antibiotics - Pregnant or breast-feeding subjects; Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment; - Immunotherapy prior to the procedure for the treatment of cancer; - Previous surgical therapy for pancreatic cancer; - Second primary malignancy with median 5 year OS < 90%, this excludes adequately treated cancers like: non-melanoma skin cancer, in situ carcinoma of the cervix uteri, superficial bladder cancer or other malignancies treated previously without signs of recurrence. - Allergy to contrast agent. - Allergy to PET tracers 18F-FDG and 18F-BMS-986192 Zr-89-Nivolumab - Any implanted stimulation device; - Portal vein or VMS stenosis > 70% (relative contra-indication) - Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study.

Study Design


Intervention

Device:
Irreversible Electroporation (IRE)
Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue
Drug:
Nivolumab
Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
Toll-Like Receptor 9
Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells. This creates a more pro-immunogenic tumor environment.

Locations

Country Name City State
Netherlands Amsterdam University Medical Centre (location VUmc) Amsterdam North-Holland

Sponsors (1)

Lead Sponsor Collaborator
Amsterdam UMC, location VUmc

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of the combination treatment IRE + immunotherapy based on adverse events Determined by the treatment related (serious) adverse events From randomization until 1 year later
Secondary Overall Survival Overall survival in terms of months From date of randomization until death, assessed up to 5 years
Secondary Progression-Free Survival Progression-free survival in terms of months From date of randomization until unequivocal disease progression, assessed up to 5 years
Secondary Immunomodulation (local) The local immune response will be assessed using flow cytometry and immunohistochemistry of 2 biopsies (1x primary, 1x metastasis). Markers include those of T-cells, dendritic cells and others. Biopsies taken at T=0 (prior to treatment), T=2 weeks and T=6 weeks
Secondary Immunomodulation (systemic) The systemic immune response will be assessed using flow cytometry of peripheral blood. Markers include those of T-cells, dendritic cells, MDSCs, NK cells. Blood taken at T=0 (prior to treatment), T=2 weeks and T=6 weeks
Secondary Tumor Response on Imaging Tumor response will be assessed using PET-CT scans: tracer uptake of FDG and PD-L1. CT scans will be employed to determine tumor response based on the RECIST criteria. PET scans at T= 0 (prior to treatment), T= 6 weeks and T=3months. CT scans will be made at T= 0 (prior to treatment), T= 6 weeks, T=3months, followed by a scan every subsequent 3 months (T=6m,9m,12m etc) until unequivocal disease progression.
Secondary Quality of Life throughout treatment based on overall health Based on the following EORTC questionnaire: EQ-5D-L5. Question types include: scale 1-5 Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
Secondary Quality of Life throughout treatment based on specific health questions Based on the following EORTC questionnaire: QLQ-C30 Question types include: scale 1-5, scale 1-7 Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
Secondary Quality of Life throughout treatment based on Chemotherapy-Induced Peripheral Neuropathy Based on the following EORTC questionnaire: QLQ-CIPN20 Question types include: scale 1-4 Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
Secondary Quality of Life throughout treatment specifically in patients with pancreatic cancer Based on the following EORTC questionnaire: QLQ-PAN26 Question types include: scale 1-4 Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
Secondary Quality of Life throughout treatment based on the patient's happiness and emotional functioning Based on the following questionnaire: QLQ-HAPINES Question types include: scale 1-10 Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
Secondary Quality of Life throughout treatment based on anxiety and depression Based on the following questionnaire: QLQ-HADS Question types include: scale 1-4 Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
Secondary Quality of Life throughout treatment based on a patient's psychological state regarding their disease Based on the following questionnaire: QLQ-WOPS Question types include: scale 1-4, scale 1-10, yes/no, open Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
Secondary Quality of Life throughout treatment based on (decreased) pancreatic functionality Based on the following questionnaire: EPI Question types include: 5 optional answers, scale, 1-4, scale 1-5, yes/no, open Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
Secondary Pain based on the Visual Analog Score (VAS) The pain questionnaire is based on the VAS and includes scale type questions (1 - 10) with higher scores referring to more pain. Pain will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study